Dr. Borgen on Advancements With HER2+ Breast Cancer

Patrick Borgen, MD
Published: Thursday, Nov 16, 2017



Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

The view of HER2-positive breast cancer has changed, explains Borgen. Previously, HER2-positive breast cancer was thought to be the worst result a biopsy could detect, but targeted treatments have since revolutionized outcomes.
 


Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

The view of HER2-positive breast cancer has changed, explains Borgen. Previously, HER2-positive breast cancer was thought to be the worst result a biopsy could detect, but targeted treatments have since revolutionized outcomes.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x